BAM
DNA icon

Brave Asset Management’s Ginkgo Bioworks DNA Stock Holding History

Brave Asset Management’s Portfolio DNA Stock Details DNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-625
Closed -$8.36K – 173
2024
Q2 		$8.36K Hold
625
– – ﹤0.01% 157
2024
Q1 		$29K Hold
625
– – 0.01% 156
2023
Q4 		$42.3K Hold
625
– – 0.01% 149
2023
Q3 		$45.3K Hold
625
– – 0.01% 141
2023
Q2 		$46.5K Buy
+625
New +$37K 0.01% 144

Other funds holding DNA

Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ACG
Anchorage Capital Group New York $450M AUM 41.75% 1-Year Est. Return
Legal & General Group
Legal & General Group London, United Kingdom $480B AUM 42.84% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $1.1B AUM 197.64% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Brave Asset Management's DNA Position: Q3 2024 in Review

Brave Asset Management sold out of Ginkgo Bioworks (DNA) in Q3 2024, closing a stake of 625 shares — an estimated $8.36K sold.

Brave Asset Management first reported a position in DNA in Q2 2023 and held it in 5 quarters. The position peaked at $46.5K in Q2 2023. 159 funds tracked by Wall St. Rank hold DNA as of Q3 2024.

  • Brave Asset Management reported no remaining Ginkgo Bioworks position as of Q3 2024 after selling out during the quarter.
  • Brave Asset Management sold 625 Ginkgo Bioworks shares in Q3 2024, an estimated $8.36K.
  • Brave Asset Management first reported a position in Ginkgo Bioworks in Q2 2023 and held it in 5 quarters.
  • Brave Asset Management's Ginkgo Bioworks position peaked at $46.5K in Q2 2023.
  • 159 funds tracked by Wall St. Rank held Ginkgo Bioworks as of Q3 2024.

Based on Brave Asset Management's 13F filing for Q3 2024, filed 10 Oct 2024.